Nov 17, 2022 / 08:00AM GMT
Kelly Shi - Jefferies - Analyst
Good morning, everyone. Thank you for attending Jefferies London Healthcare Conference. My name is Kelly Shi, one of the biotech analysts at Jefferies.
It is our great pleasure to host Mr. Kevin Lee, CEO of Bicycle Therapeutics. We also have Mr. Lee Kalowski, CFO; and Dr. Nick Keen, Chief Scientific Officer; and Mr. Dominic Smethurst, Chief Medical Officer, for a fireside chat. Welcome, everyone.
Questions and Answers:
Kelly Shi - Jefferies - AnalystAnd first, maybe would you like to give a brief introduction of the company and also discuss where do you see the application of Bicycle molecules to the broader space of drug development?
Kevin Lee - Bicycle Therapeutics plc - CEO
Hi. Thanks, Kelly. And many thanks to Jefferies for the invitation and, obviously, the audience for getting up so early this morning.
Bicycle is a company that was founded by Sir Greg Winter. Many of you all know Sir Greg Winter from his pioneering work in antibodies and peptides, and
Trustpilot
